{
    "hands_on_practices": [
        {
            "introduction": "Mastering clinical pharmacogenomics begins with the fundamental workflow of translating a patient's genetic data into a concrete clinical action. This first practice exercise guides you through this core process using the classic example of the CYP2D6 gene and the prodrug codeine. By calculating a patient's enzyme activity score from their diplotype, you will determine their metabolizer phenotype and make a definitive prescribing decision, building the foundational skill of genotype-to-phenotype translation .",
            "id": "4814034",
            "problem": "A $55$-year-old patient with chronic osteoarthritic pain is being evaluated for analgesic therapy. Cytochrome P450 $2\\mathrm{D}6$ (CYP2D6) genotyping reveals the diplotype $CYP2D6~^\\ast1\\text{x}3 / CYP2D6~^\\ast4$. The care team is considering codeine as an analgesic option. Use the following foundational facts and definitions to derive the patient’s predicted metabolizer status and translate it into a prescribing decision:\n\n- Cytochrome P450 $2\\mathrm{D}6$ (CYP2D6) enzyme function is determined by the sum of functional contributions from each gene copy. A normal function allele contributes $1$ to the activity score, a decreased function allele contributes $0.5$, and a no-function allele contributes $0$. Copy number variation multiplies the contribution proportionally (for example, a normal function allele present in $3$ copies contributes $3$). The overall activity score is the sum across all copies.\n\n- Phenotype assignment is based on the activity score using widely adopted clinical implementation thresholds: poor metabolizer if $AS = 0$, intermediate metabolizer if $AS \\in [0.25, 1]$, normal metabolizer if $AS \\in [1.25, 2.25]$, and ultrarapid metabolizer if $AS > 2.25$.\n\n- Codeine is a prodrug that requires bioactivation to morphine predominantly via CYP2D6. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend avoiding codeine in both poor and ultrarapid metabolizers due to lack of efficacy in poor metabolizers ($AS = 0$) and risk of morphine overexposure and toxicity in ultrarapid metabolizers ($AS > 2.25$).\n\nTasks:\n\n1. Compute the patient’s CYP2D6 activity score $AS$ from the provided diplotype.\n2. Assign the metabolizer phenotype category using the thresholds provided.\n3. Translate the phenotype into a prescribing implication specifically for codeine by defining a dose scaling factor $\\alpha$ relative to the standard codeine starting dose, where complete avoidance corresponds to $\\alpha = 0$ and proceeding with the standard dose corresponds to $\\alpha = 1$. If the recommendation is to avoid codeine, set $\\alpha = 0$.\n\nExpress the final answer as the single value $\\alpha$ (dimensionless). No rounding is required.",
            "solution": "The problem is deemed valid as it is scientifically grounded in the principles of clinical pharmacogenomics, is well-posed with a unique and stable solution, and is expressed in objective, formalizable language. All necessary data and definitions for the derivation are provided. The solution proceeds by executing the three specified tasks in sequence.\n\nThe core of the problem is to determine a patient-specific prescribing decision for codeine based on their genetic makeup. This involves a three-step process: first, calculating a quantitative 'activity score' from the patient's genotype; second, translating this score into a qualitative phenotype category; and third, applying a clinical guideline to this phenotype to arrive at a therapeutic recommendation, which is then encoded as the parameter $\\alpha$.\n\n**Step 1: Compute the CYP2D6 Activity Score ($AS$)**\n\nThe patient's diplotype is given as $CYP2D6~^\\ast1\\text{x}3 / CYP2D6~^\\ast4$. This notation describes the two alleles of the $CYP2D6$ gene inherited by the patient. One allele is a triplication of the $^\\ast1$ variant ($^\\ast1\\text{x}3$), and the other is the $^\\ast4$ variant.\n\nTo compute the total activity score ($AS$), we sum the contributions of each allele. The problem provides the rules for this calculation, but requires knowledge of the functional status of the specific alleles, $^\\ast1$ and $^\\ast4$. Within the standard nomenclature of pharmacogenomics:\n- The $CYP2D6~^\\ast1$ allele is the reference for normal (or wild-type) function. Its activity value is $1$.\n- The $CYP2D6~^\\ast4$ allele is the most common non-functional (or no-function) allele. Its activity value is $0$.\n\nThe contribution of the first part of the diplotype, $^\\ast1\\text{x}3$, is calculated by multiplying the number of gene copies by the activity value of the $^\\ast1$ allele.\n$$ \\text{Contribution}_{(^\\ast1\\text{x}3)} = (\\text{Number of copies}) \\times (\\text{Activity value of } ^\\ast1) = 3 \\times 1 = 3 $$\n\nThe contribution of the second part of the diplotype, $^\\ast4$, is calculated by multiplying the number of gene copies (which is implicitly $1$) by the activity value of the $^\\ast4$ allele.\n$$ \\text{Contribution}_{(^\\ast4)} = (\\text{Number of copies}) \\times (\\text{Activity value of } ^\\ast4) = 1 \\times 0 = 0 $$\n\nThe total $CYP2D6$ activity score ($AS$) is the sum of the contributions from both alleles.\n$$ AS = \\text{Contribution}_{(^\\ast1\\text{x}3)} + \\text{Contribution}_{(^\\ast4)} = 3 + 0 = 3 $$\n\n**Step 2: Assign the Metabolizer Phenotype**\n\nThe problem provides the following thresholds for phenotype assignment based on the activity score $AS$:\n- Poor metabolizer (PM): $AS = 0$\n- Intermediate metabolizer (IM): $AS \\in [0.25, 1]$\n- Normal metabolizer (NM): $AS \\in [1.25, 2.25]$\n- Ultrarapid metabolizer (UM): $AS > 2.25$\n\nThe calculated activity score for the patient is $AS = 3$. We compare this value to the given thresholds. The condition $3 > 2.25$ is satisfied. Therefore, the patient's predicted metabolizer phenotype is ultrarapid metabolizer (UM).\n\n**Step 3: Translate Phenotype to Prescribing Implication ($\\alpha$)**\n\nThe problem states that codeine is a prodrug requiring bioactivation to morphine via the CYP2D6 enzyme. The provided clinical guideline dictates therapeutic action based on metabolizer status: avoid codeine in both poor metabolizers (PM) and ultrarapid metabolizers (UM).\n\nThe patient has been identified as an ultrarapid metabolizer ($AS=3$), a group in which codeine should be avoided due to the high risk of converting codeine to morphine too rapidly and extensively, leading to potential morphine toxicity (e.g., respiratory depression).\n\nThe problem defines a dose scaling factor $\\alpha$ to represent this decision, where $\\alpha = 0$ corresponds to complete avoidance of the drug. Since the clinical recommendation for a CYP2D6 ultrarapid metabolizer is to avoid codeine, the appropriate value for the scaling factor is $0$.\n$$ \\alpha = 0 $$",
            "answer": "$$\\boxed{0}$$"
        },
        {
            "introduction": "Beyond qualitative recommendations, a deeper understanding of pharmacogenomics requires quantifying how genetic variations impact drug disposition and patient outcomes. This practice explores the pharmacokinetic mechanism linking genotype to clinical risk. You will use fundamental principles to calculate how a genetically determined reduction in drug clearance ($CL$) increases systemic drug exposure ($AUC$) and then apply a pharmacodynamic model to translate this increased exposure into a specific probability of toxicity .",
            "id": "4814056",
            "problem": "A transplant recipient in internal medicine is initiated on an oral calcineurin inhibitor whose exposure is governed by linear pharmacokinetics at therapeutic concentrations. Assume a one-compartment model with first-order elimination for a single oral dose, immediate absorption, and constant parameters over the dosing interval. The Area Under the plasma concentration–time Curve (AUC), oral bioavailability (F), dose (D), and clearance (CL) are related through the standard mass-balance and first-order decay principles for linear pharmacokinetics. In this patient, the toxicity risk is modeled as a monotonic function of exposure using a logistic link: the probability of clinically significant toxicity in the upcoming cycle is\n$$P(\\text{toxicity} \\mid \\text{AUC}) = \\frac{1}{1 + \\exp\\!\\big(-\\beta \\, (\\text{AUC} - A^{*})\\big)},$$\nwhere $\\beta$ is a sensitivity parameter and $A^{*}$ is an exposure threshold.\n\nYou are told the following scientifically plausible values:\n- Oral bioavailability $F = 0.8$ (dimensionless).\n- Oral dose $D = 100$ $\\text{mg}$.\n- Normal metabolizer clearance $CL_{\\text{NM}} = 20$ $\\text{L} \\cdot \\text{h}^{-1}$.\n- Poor metabolizer genotype reduces clearance to $CL_{\\text{PM}} = \\alpha \\, CL_{\\text{NM}}$ with $\\alpha = 0.3$ (dimensionless), reflecting decreased enzymatic activity.\n- Toxicity model parameters $\\beta = 0.2$ $(\\text{mg} \\cdot \\text{h} / \\text{L})^{-1}$ and $A^{*} = 8$ $\\text{mg} \\cdot \\text{h} / \\text{L}$.\n\nStarting from fundamental definitions and laws appropriate for linear pharmacokinetics, derive how the genotype-driven change in $CL$ alters $AUC$ at fixed $F$ and $D$, and then use the provided toxicity model to compute the probability of toxicity $P(\\text{toxicity} \\mid \\text{AUC}_{\\text{PM}})$ for the poor metabolizer. Express your final numeric answer as a decimal and round to four significant figures. No units are required for the probability.",
            "solution": "The problem is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. All necessary parameters are provided, and the scenario is a standard application of fundamental principles in clinical pharmacogenomics. The problem is therefore deemed valid and a solution will be provided.\n\nThe analysis begins with the fundamental principles of linear pharmacokinetics. For a drug administered via a route other than intravenous, not all of the dose $D$ may reach systemic circulation. The fraction that does is termed the oral bioavailability, $F$. The total amount of drug that becomes systemically available is therefore the product $F \\cdot D$.\n\nIn a one-compartment model with first-order elimination, the concentration of the drug in the plasma, $C(t)$, decays over time. The total exposure to the drug is quantified by the Area Under the plasma concentration–time Curve, $\\text{AUC}$, which is the integral of the concentration over all time from $t=0$ to $t=\\infty$:\n$$ \\text{AUC} = \\int_0^\\infty C(t) dt $$\nClearance, $CL$, is defined as the volume of plasma cleared of the drug per unit time. The rate of elimination of the drug from the body is given by the product of clearance and the plasma concentration:\n$$ \\text{Rate of elimination} = CL \\cdot C(t) $$\nAccording to the principle of mass balance, over an infinite time horizon, the total amount of drug eliminated must equal the total amount of drug that entered the systemic circulation. We can express this by integrating the rate of elimination over time:\n$$ \\text{Total amount eliminated} = \\int_0^\\infty CL \\cdot C(t) dt $$\nSince clearance $CL$ is assumed to be a constant parameter in linear kinetics, it can be factored out of the integral:\n$$ \\text{Total amount eliminated} = CL \\int_0^\\infty C(t) dt = CL \\cdot \\text{AUC} $$\nEquating the total amount of drug absorbed systemically with the total amount eliminated, we have:\n$$ F \\cdot D = CL \\cdot \\text{AUC} $$\nRearranging this equation yields the fundamental relationship for calculating $\\text{AUC}$:\n$$ \\text{AUC} = \\frac{F \\cdot D}{CL} $$\nThis equation shows that for a fixed dose $D$ and bioavailability $F$, the exposure $\\text{AUC}$ is inversely proportional to the clearance $CL$. A genotype-driven change in $CL$ will thus alter $\\text{AUC}$ inversely.\n\nThe problem provides parameters for a normal metabolizer ($NM$) and a poor metabolizer ($PM$). We are tasked with calculating the toxicity risk for a $PM$ patient.\nThe first step is to calculate the clearance for the poor metabolizer, $CL_{\\text{PM}}$.\nGiven:\n- Normal metabolizer clearance, $CL_{\\text{NM}} = 20$ $\\text{L} \\cdot \\text{h}^{-1}$.\n- The reduction factor for a poor metabolizer, $\\alpha = 0.3$.\nThe clearance for a poor metabolizer is:\n$$ CL_{\\text{PM}} = \\alpha \\cdot CL_{\\text{NM}} $$\nSubstituting the given values:\n$$ CL_{\\text{PM}} = 0.3 \\cdot 20 \\, \\text{L} \\cdot \\text{h}^{-1} = 6 \\, \\text{L} \\cdot \\text{h}^{-1} $$\nThe next step is to calculate the $\\text{AUC}$ for this poor metabolizer, which we denote as $\\text{AUC}_{\\text{PM}}$.\nGiven:\n- Oral bioavailability, $F = 0.8$.\n- Oral dose, $D = 100$ $\\text{mg}$.\nUsing the derived formula for $\\text{AUC}$:\n$$ \\text{AUC}_{\\text{PM}} = \\frac{F \\cdot D}{CL_{\\text{PM}}} $$\nSubstituting the values:\n$$ \\text{AUC}_{\\text{PM}} = \\frac{0.8 \\cdot 100 \\, \\text{mg}}{6 \\, \\text{L} \\cdot \\text{h}^{-1}} = \\frac{80}{6} \\, \\text{mg} \\cdot \\text{h} \\cdot \\text{L}^{-1} = \\frac{40}{3} \\, \\text{mg} \\cdot \\text{h} \\cdot \\text{L}^{-1} $$\nNow, we use the provided logistic model to calculate the probability of toxicity, $P(\\text{toxicity} \\mid \\text{AUC}_{\\text{PM}})$. The model is:\n$$ P(\\text{toxicity} \\mid \\text{AUC}) = \\frac{1}{1 + \\exp\\!\\big(-\\beta \\, (\\text{AUC} - A^{*})\\big)} $$\nThe given toxicity model parameters are:\n- Sensitivity parameter, $\\beta = 0.2$ $(\\text{mg} \\cdot \\text{h} \\cdot \\text{L}^{-1})^{-1}$.\n- Exposure threshold, $A^{*} = 8$ $\\text{mg} \\cdot \\text{h} \\cdot \\text{L}^{-1}$.\nWe substitute $\\text{AUC}_{\\text{PM}}$, $\\beta$, and $A^{*}$ into the model. First, we calculate the exponent, $-\\beta (\\text{AUC}_{\\text{PM}} - A^{*})$:\n$$ -\\beta (\\text{AUC}_{\\text{PM}} - A^{*}) = -0.2 \\left( \\frac{40}{3} - 8 \\right) $$\nTo combine the terms in the parenthesis, we find a common denominator:\n$$ 8 = \\frac{24}{3} $$\n$$ \\frac{40}{3} - 8 = \\frac{40}{3} - \\frac{24}{3} = \\frac{16}{3} $$\nThe exponent is therefore:\n$$ -0.2 \\cdot \\frac{16}{3} = -\\frac{1}{5} \\cdot \\frac{16}{3} = -\\frac{16}{15} $$\nNow, substitute this value back into the probability formula:\n$$ P(\\text{toxicity} \\mid \\text{AUC}_{\\text{PM}}) = \\frac{1}{1 + \\exp\\left(-\\frac{16}{15}\\right)} $$\nTo obtain the final numerical answer, we compute the value of this expression.\nThe exponent is approximately $-\\frac{16}{15} \\approx -1.0666...$\n$$ \\exp\\left(-\\frac{16}{15}\\right) \\approx 0.344158 $$\n$$ 1 + \\exp\\left(-\\frac{16}{15}\\right) \\approx 1.344158 $$\n$$ P(\\text{toxicity} \\mid \\text{AUC}_{\\text{PM}}) = \\frac{1}{1.344158} \\approx 0.743960 $$\nRounding the result to four significant figures as requested gives $0.7440$.",
            "answer": "$$\n\\boxed{0.7440}\n$$"
        },
        {
            "introduction": "Real-world clinical decision-making often involves integrating multiple, sometimes competing, variables. This final practice presents an advanced clinical scenario requiring you to synthesize a patient's pharmacogenomic profile with a significant drug-drug interaction. You will develop a comprehensive initial dosing and monitoring strategy for a narrow-therapeutic-index drug in a transplant recipient, a situation where the stakes are high and precision is paramount . This exercise showcases the application of pharmacogenomics in a complex, multi-factorial clinical context.",
            "id": "4814001",
            "problem": "A $45$-year-old man ($70$ kg) undergoes deceased-donor kidney transplantation. He is started on mycophenolate mofetil and prednisone. Infectious prophylaxis includes trimethoprim-sulfamethoxazole, valganciclovir, and fluconazole $200$ mg daily due to residence in an endemic fungal area. Liver function tests are within normal limits; there is no known hepatic disease. Therapeutic drug monitoring for tacrolimus is planned.\n\nPre-transplant pharmacogenomic testing returns cytochrome P450 family 3 subfamily A polypeptide 5 (CYP3A5) genotype $^\\ast1/^\\ast3$, consistent with an enzyme expresser phenotype. The transplant team asks you to propose an initial tacrolimus dosing and monitoring plan that integrates the patient’s genotype and the antifungal co-therapy to achieve early post-transplant target trough concentrations of $8$–$12$ ng/mL.\n\nUsing the following fundamental bases:\n- Central Dogma of Molecular Biology: DNA $\\rightarrow$ RNA $\\rightarrow$ protein. A functional CYP3A5 protein increases metabolic capacity for tacrolimus.\n- Pharmacokinetic definitions: Clearance ($CL$) is the volume of plasma cleared of drug per unit time; for a drug with linear kinetics at therapeutic concentrations, steady-state concentration $C_{ss}$ is proportional to $\\text{Dose}/CL$. For a multiple-dose regimen at steady state, the trough concentration $C_{\\min}$ depends inversely on $CL$ for a fixed dosing rate. Cytochrome P450 inhibition decreases $CL$, and increased enzyme expression increases $CL$.\n- Well-tested clinical facts: Tacrolimus is primarily metabolized by CYP3A enzymes; CYP3A5 expressers have higher tacrolimus $CL$ than non-expressers. Fluconazole is a moderate inhibitor of CYP3A4 and can reduce tacrolimus $CL$. Early post-transplant tacrolimus trough targets are commonly $8$–$12$ ng/mL, with measurement immediately before the next dose (true trough).\n\nWhich of the following is the most appropriate initial tacrolimus dosing and monitoring plan for this patient?\n\nA. Initiate tacrolimus at $0.20$ mg/kg/day divided every $12$ hours ($\\approx 7$ mg q$12$h), obtain the first trough on post-operative day $4$, target $8$–$12$ ng/mL, and adjust by $10\\%$ no more than once weekly.\n\nB. Initiate tacrolimus at $0.10$ mg/kg/day divided every $12$ hours ($\\approx 3.5$ mg q$12$h), obtain true troughs (sample at $t=12$ hours, immediately before the morning dose) daily for the first $3$–$5$ days, target $8$–$12$ ng/mL, and adjust the dose in $25$–$33\\%$ increments based on each trough, rechecking a trough within $2$–$3$ doses after every change; maintain fluconazole and account for its inhibitory effect when interpreting levels.\n\nC. Initiate tacrolimus as a fixed dose of $2$ mg every $12$ hours irrespective of weight or genotype, obtain peak concentrations at $t=2$ hours post-dose, target $20$–$30$ ng/mL, and adjust doses by doubling or halving as needed; discontinue fluconazole to avoid drug–drug interactions.\n\nD. Initiate tacrolimus at $0.18$ mg/kg/day for genotype, then reduce by $50\\%$ due to fluconazole to $0.09$ mg/kg/day ($\\approx 3$ mg q$12$h), obtain troughs every $72$ hours, target $5$–$8$ ng/mL in the first month, and only change the dose if the area under the concentration–time curve (AUC) deviates outside the population mean by $>2$ standard deviations.",
            "solution": "The user has provided a clinical problem in transplant pharmacogenomics and asks for the most appropriate initial dosing and monitoring plan for tacrolimus from a set of options.\n\n### Step 1: Extract Givens\n\n-   Patient: A $45$-year-old man.\n-   Weight: $70$ kg.\n-   Clinical Context: Deceased-donor kidney transplantation.\n-   Concomitant Medications: Mycophenolate mofetil, prednisone, trimethoprim-sulfamethoxazole, valganciclovir, and fluconazole $200$ mg daily.\n-   Organ Function: Liver function tests are within normal limits; no known hepatic disease.\n-   Pharmacogenomic Test Result: Cytochrome P450 family 3 subfamily A polypeptide 5 (CYP3A5) genotype is $^\\ast1/^\\ast3$.\n-   Inferred Phenotype: Enzyme expresser.\n-   Therapeutic Goal: Achieve early post-transplant target trough concentrations of $8$–$12$ ng/mL.\n-   Fundamental Principles Provided:\n    1.  A functional CYP3A5 protein increases the metabolic capacity for tacrolimus.\n    2.  Pharmacokinetic relations: Steady-state concentration $C_{ss}$ is proportional to $\\text{Dose}/CL$. Trough concentration $C_{\\min}$ is inversely proportional to clearance ($CL$). CYP450 inhibition decreases $CL$; increased enzyme expression increases $CL$.\n    3.  Clinical facts: Tacrolimus is metabolized by CYP3A enzymes. CYP3A5 expressers have higher tacrolimus $CL$. Fluconazole is a moderate inhibitor of CYP3A4 and reduces tacrolimus $CL$. The target trough range is $8$–$12$ ng/mL, measured immediately before the next dose.\n\n### Step 2: Validate Using Extracted Givens\n\n-   **Scientifically Grounded**: The problem is based on established principles of pharmacokinetics, pharmacogenomics (PGx), and clinical pharmacology in transplantation. The roles of CYP3A5 in tacrolimus metabolism, drug-drug interactions (DDIs) involving azole antifungals, and therapeutic drug monitoring (TDM) are all scientifically valid and clinically relevant.\n-   **Well-Posed**: The problem is clearly defined. It presents a specific patient case with all necessary data (age, weight, genotype, co-medications) and asks for the selection of the most appropriate management plan based on a given set of principles and a target therapeutic window. A single best answer can be determined through logical deduction.\n-   **Objective**: The problem statement is objective, using precise medical and scientific terminology. It is free from subjective claims or ambiguity.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. I will proceed with a full solution and evaluation of the options.\n\n### Derivation of the Optimal Plan\n\nThe core of this problem is to integrate two opposing factors that influence tacrolimus clearance ($CL$) to determine the appropriate initial dose and monitoring strategy.\n\n1.  **Effect of Pharmacogenotype**: The patient's genotype is CYP3A5 $^\\ast1/^\\ast3$, indicating the presence of one functional allele ($^\\ast1$) and one non-functional allele ($^\\ast3$). This makes the patient a \"CYP3A5 expresser.\" According to the provided principles, increased enzyme expression leads to increased metabolic capacity. Therefore, the patient's intrinsic tacrolimus clearance ($CL$) is expected to be higher than that of a non-expresser (e.g., a $^\\ast3/^\\ast3$ individual). In the absence of other factors, a CYP3A5 expresser typically requires a higher initial dose of tacrolimus, often $1.5$ to $2.0$ times the standard dose, to achieve the target concentration. A standard starting dose is often in the range of $0.10$ mg/kg/day. Thus, a genotype-guided dose for this patient might be initially estimated at $0.15$–$0.20$ mg/kg/day.\n\n2.  **Effect of Drug-Drug Interaction (DDI)**: The patient is receiving fluconazole ($200$ mg daily), which is stated to be a moderate inhibitor of CYP3A4. Since tacrolimus is primarily metabolized by CYP3A enzymes (both CYP3A4 and CYP3A5), this inhibition will decrease the metabolic clearance of tacrolimus. A moderate inhibitor can reduce tacrolimus $CL$ significantly, often necessitating a dose reduction of $30\\%$–$60\\%$.\n\n3.  **Integrated Assessment**: We must consider the net effect of these two competing influences:\n    -   CYP3A5 expression $\\rightarrow$ Increases $CL$ (requires higher dose).\n    -   Fluconazole inhibition $\\rightarrow$ Decreases $CL$ (requires lower dose).\n\n    The standard clinical approach, endorsed by expert guidelines such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), for a CYP3A5 expresser who is also receiving a moderate CYP3A inhibitor is to recognize that these two effects will approximately counteract each other. Therefore, the recommendation is to initiate tacrolimus at a standard starting dose, i.e., the dose that would be used for a CYP3A5 non-expresser without an inhibitor. A typical standard starting dose is $0.10$ mg/kg/day.\n\n    Let's calculate the dose based on this reasoning:\n    -   Dose rate = $0.10$ mg/kg/day\n    -   Patient weight = $70$ kg\n    -   Total daily dose = $0.10 \\text{ mg/kg/day} \\times 70 \\text{ kg} = 7$ mg/day\n    -   Tacrolimus is administered every $12$ hours (q$12$h), so the dose is divided by $2$.\n    -   Initial dose = $7 \\text{ mg} / 2 = 3.5$ mg q$12$h.\n\n4.  **Monitoring Plan**: Tacrolimus has a narrow therapeutic window and high inter-individual pharmacokinetic variability, which is further complicated in this case by the PGx-DDI interaction and the dynamic physiology of the early post-transplant period. Therefore, an aggressive TDM strategy is warranted.\n    -   **Frequency**: Trough concentrations should be measured frequently, typically daily, for the first several days post-transplant to guide dose adjustments.\n    -   **Target**: The target is explicitly given as $8$–$12$ ng/mL.\n    -   **Adjustment**: Dose adjustments should be made promptly based on trough levels to bring the concentration into the therapeutic range quickly, minimizing the risk of rejection (subtherapeutic levels) or nephrotoxicity (supratherapeutic levels). Adjustments in the range of $25\\%$–$33\\%$ are common and allow for titration without excessive over- or under-shooting.\n    -   **Follow-up**: After any dose adjustment, a new trough level should be checked within a few doses (e.g., $24$–$48$ hours) to assess the impact of the change.\n\n### Option-by-Option Analysis\n\n**A. Initiate tacrolimus at $0.20$ mg/kg/day divided every $12$ hours ($\\approx 7$ mg q$12$h), obtain the first trough on post-operative day $4$, target $8$–$12$ ng/mL, and adjust by $10\\%$ no more than once weekly.**\n-   **Dosing**: A dose of $0.20$ mg/kg/day ($14$ mg/day total, or $7$ mg q$12$h) is appropriate for a CYP3A5 expresser *without* an inhibitor. This plan completely ignores the potent inhibitory effect of fluconazole and would almost certainly lead to severe and dangerous tacrolimus toxicity.\n-   **Monitoring**: Waiting until post-operative day $4$ for the first level is too long. The adjustment strategy of only $10\\%$ once weekly is far too slow and conservative for the critical initial post-transplant phase.\n-   **Verdict**: **Incorrect**.\n\n**B. Initiate tacrolimus at $0.10$ mg/kg/day divided every $12$ hours ($\\approx 3.5$ mg q$12$h), obtain true troughs (sample at $t=12$ hours, immediately before the morning dose) daily for the first $3$–$5$ days, target $8$–$12$ ng/mL, and adjust the dose in $25$–$33\\%$ increments based on each trough, rechecking a trough within $2$–$3$ doses after every change; maintain fluconazole and account for its inhibitory effect when interpreting levels.**\n-   **Dosing**: The initial dose of $0.10$ mg/kg/day ($3.5$ mg q$12$h) is perfectly aligned with our derived strategy of balancing the CYP3A5 expresser status with the fluconazole-induced inhibition by starting at a standard dose.\n-   **Monitoring**: The TDM plan is excellent. Daily troughs for the first $3$–$5$ days, use of true troughs, appropriate adjustment increments ($25\\%$–$33\\%$), and rapid re-checking of levels after a change all represent best practices for early post-transplant tacrolimus management.\n-   **Overall Strategy**: This plan correctly synthesizes all the patient's data into a coherent, safe, and effective clinical strategy. It correctly advises to manage the DDI, not avoid it by stopping a necessary medication.\n-   **Verdict**: **Correct**.\n\n**C. Initiate tacrolimus as a fixed dose of $2$ mg every $12$ hours irrespective of weight or genotype, obtain peak concentrations at $t=2$ hours post-dose, target $20$–$30$ ng/mL, and adjust doses by doubling or halving as needed; discontinue fluconazole to avoid drug–drug interactions.**\n-   **Dosing**: A fixed dose of $2$ mg q$12$h ($4$ mg/day) ignores weight-based dosing, which is standard practice for tacrolimus initiation. This dose is likely to be subtherapeutic for a $70$ kg patient.\n-   **Monitoring**: TDM for tacrolimus is based on trough ($C_{\\min}$), not peak ($C_{max}$), concentrations. The target range of $20$–$30$ ng/mL for peaks is not standard. Adjustments by doubling or halving are overly aggressive.\n-   **Clinical Management**: Discontinuing necessary fungal prophylaxis (fluconazole) is clinically unsound. The correct approach is to manage the DDI.\n-   **Verdict**: **Incorrect**.\n\n**D. Initiate tacrolimus at $0.18$ mg/kg/day for genotype, then reduce by $50\\%$ due to fluconazole to $0.09$ mg/kg/day ($\\approx 3$ mg q$12$h), obtain troughs every $72$ hours, target $5$–$8$ ng/mL in the first month, and only change the dose if the area under the concentration–time curve (AUC) deviates outside the population mean by $>2$ standard deviations.**\n-   **Dosing**: The dose calculation ($0.09$ mg/kg/day, or $\\approx 3$ mg q$12$h) is reasonable and arithmetically close to the dose in option B. The logic of starting with a genotype-adjusted dose and then reducing for the inhibitor is a valid thought process.\n-   **Monitoring**: Monitoring only every $72$ hours is not frequent enough for the initial titration period.\n-   **Target**: The target of $5$–$8$ ng/mL directly contradicts the problem statement's required target of $8$–$12$ ng/mL.\n-   **Adjustment Criteria**: The proposed adjustment rule based on AUC and population standard deviations is clinically impractical, not used in routine practice, and nonsensical for real-time dose adjustments based on single trough values.\n-   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}